National cooperative group trial seeks to cut in half early mortality rates for rare leukemia
(Medical College of Georgia at Augusta University) A national cooperative group trial is making a handful of the country's experts in a rare leukemia available around the clock, with the goal of cutting by more than half the high mortality rates that occur in the difficult first few weeks of treatment.Induction mortality for treatment of acute promyelocytic leukemia, or APL, can be as high as 30 percent, but for patients who survive those first few weeks, survival rates can soar beyond 90 percent, making it the most curable leukemia.
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL); Safety and Efficacy of CD19 UCAR-T Cells Intervention: Biological: CD19 UCARTcells Sponsor: Shanghai Longyao Biotechnology Inc., Ltd. Recruiting
High WT1 expression after allogeneic hematologic stem cell transplantation (allo-HSCT) can strongly predict relapse in acute myeloid leukemia (AML). However, the cutoff values obtained were inconsistent. The precise cutoff values may be optimized through subtype analysis, and the RUNX1-RUNX1T1 fusion transcript provides an ideal reference. RUNX1-RUNX1T1 and WT1 transcript levels were simultaneously measured in 1,299 bone marrow samples serially collected from 176 t(8;21) AML patients after receiving allo-HSCTfor.
Myeloid neoplasms are a heterogenous group of neoplasms including acute myeloid leukemia (AML), myeloproliferative neoplasms, myelodysplastic syndrome, and myeloproliferative neoplasms / myelodysplastic syndrome. Genetic abnormalities are used as diagnostic, prognostic, and predictive biomarkers in patients with these diseases. Here, we describe the clinical validation of the Oncomine Myeloid Research (OMR) next-generation sequencing panel that interrogates for 40 genes and 29 fusion genes commonly seen in myeloid neoplasms.
Blood Cancer Journal, Published online: 18 November 2019; doi:10.1038/s41408-019-0251-3Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT
Publication date: Available online 17 November 2019Source: Journal of Pharmaceutical and Biomedical AnalysisAuthor(s): Pelin Şenel, Soykan Agar, V. Oyku Sayin, Filiz Altay, Mine Yurtsever, Ayşegül GölcüAbstractFludarabine is a purine derivative, anti-neoplastic drug and is still being used in the treatments of chronic lymphocytic leukemia, small lymphocytic lymphoma, acute myeloid leukemia, Non-Hodgkin’s lymphoma. It achieves its function by interacting with DNA. Therefore, the binding interactions of such drugs with deoxyribonucleic acid (DNA) is an important subject for pharmaceutical and biochemic...
Authors: Fathi E, Sanaat Z, Farahzadi R Abstract Drug resistance in cancer, especially in leukemia, creates a dilemma in treatment planning. Consequently, studies related to the mechanisms underlying drug resistance, the molecular pathways involved in this phenomenon, and alternate therapies have attracted the attention of researchers. Among a variety of therapeutic modalities, mesenchymal stem cells (MSCs) are of special interest due to their potential clinical use. Therapies involving MSCs are showing increasing promise in cancer treatment and anticancer drug screening applications; however, results have been inc...
Conclusion: Among the AML patients, intermediate-risk NPM1 wt/FLT3-ITDneg/low patients and favorable-risk patients showed similar OS rates. Our results suggested that allo-HCT might have limited clinical benefit for the intermediate-risk NPM1 wt/FLT3-ITDneg/low patients. Well controlled studies are needed to confirm the current results. PMID: 31730679 [PubMed]
Conclusion: The main nutritional and environmental risk factors found were early complementary feeding, cow’s milk prior to 1 year of age, a duration of breastfeeding of fewer than 6 months, birth weight of>3,500 g, a positive smoking habit in the children’s parents, as well as exposure to arsenic in drinking water. Identification of these risk factors could constitute an input for integrating novel prevention alternatives and the nutritional management of leukemia.
We present a novel, TdT and CD3 negative, aggressive early T-cell precursor LBL (ETP-LBL) initially misdiagnosed as a high grade B-cell lymphoma due to expression of CD79a and the erroneous detection of BCL2/IGH fusion. The patient was eventually evaluated using molecular diagnostic techniques, including fluorescence in situ hybridization (FISH) and next generation sequencing (NGS) assays that demonstrated PICALM-MLLT10 fusion and a NOTCH1 mutation in the absence of BCL2/IGH fusion. The use of NGS, specifically mate-pair sequencing (MPseq), subsequently confirmed an in-frame PICALM-MLLT10 fusion. Our retrospective analysis...